Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
5.34
-0.36 (-6.32%)
Mar 31, 2025, 1:17 PM EDT - Market open

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.

The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.

Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Astria Therapeutics, Inc.
Astria Therapeutics logo
Country United States
Founded 2008
IPO Date Jun 25, 2015
Industry Biotechnology
Sector Healthcare
Employees 78
CEO Jill Milne

Contact Details

Address:
22 Boston Wharf Road, 10th floor
Boston, Massachusetts 02210
United States
Phone 617 349 1971
Website astriatx.com

Stock Details

Ticker Symbol ATXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001454789
CUSIP Number 04635X102
ISIN Number US04635X1028
SIC Code 2834

Key Executives

Name Position
Jill C. Milne Ph.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Christopher J. Morabito M.D. Chief Medical Officer
Benjamin S. Harshbarger J.D. Chief Legal Officer
Keri McGrail Chief Human Resources Officer
Andrea L. Matthews Chief Business Officer
Andrew A. Komjathy Chief Commercial Officer
John Ruesch Senior Vice President of Pharmaceutical Sciences and Technical Operations
Rafif Dagher Senior Vice President and Head of Discovery, Nonclinical Development and Translational Research

Latest SEC Filings

Date Type Title
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 28, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 7, 2025 SCHEDULE 13G Filing
Dec 19, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals